JPH04243822A - Calcium antagonist - Google Patents
Calcium antagonistInfo
- Publication number
- JPH04243822A JPH04243822A JP3022643A JP2264391A JPH04243822A JP H04243822 A JPH04243822 A JP H04243822A JP 3022643 A JP3022643 A JP 3022643A JP 2264391 A JP2264391 A JP 2264391A JP H04243822 A JPH04243822 A JP H04243822A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- water
- calcium
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title claims abstract description 11
- 239000000480 calcium channel blocker Substances 0.000 title claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 claims description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 abstract description 9
- -1 phenol compound Chemical class 0.000 abstract description 7
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 abstract description 6
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 abstract description 6
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011575 calcium Substances 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- DMRITABJOXETEI-UHFFFAOYSA-N schizotenuin A Natural products Cc1cc(CC(OC(=O)C=Cc2cc(O)c3oc(c4ccc(O)cc4C)c(C(=O)OC(Cc5ccc(O)c(O)c5)C(=O)O)c3c2)C(=O)O)ccc1O DMRITABJOXETEI-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 abstract description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 abstract description 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 206010003119 arrhythmia Diseases 0.000 abstract description 2
- 230000006793 arrhythmia Effects 0.000 abstract description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 abstract description 2
- 229940074360 caffeic acid Drugs 0.000 abstract description 2
- 235000004883 caffeic acid Nutrition 0.000 abstract description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 abstract description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 abstract description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 abstract description 2
- 229940025878 hesperidin Drugs 0.000 abstract description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 abstract description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 abstract description 2
- 235000009498 luteolin Nutrition 0.000 abstract description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 abstract description 2
- 241000951376 Schizonepeta tenuifolia Species 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000010828 elution Methods 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000002213 calciumantagonistic effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960005425 nitrendipine Drugs 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- LDTDRTSKWGQBAA-IPOZFMEPSA-N 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 LDTDRTSKWGQBAA-IPOZFMEPSA-N 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- FBOPMOBFNZUGSZ-UHFFFAOYSA-N 7-O-beta-D-Glucopyranoside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C(OC)=C(OC4C(C(O)C(O)C(CO)O4)O)C=C3O2)O)=C1 FBOPMOBFNZUGSZ-UHFFFAOYSA-N 0.000 description 1
- IVCZEZUJCMWBBR-UHFFFAOYSA-N 7-O-beta-D-glucopyranosyl-7,3',4'-trihydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 IVCZEZUJCMWBBR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000015329 Aeginetia indica Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000195888 Physcomitrella Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- NBSPOAXOBIRHSH-UHFFFAOYSA-N luteolin 7-O-beta-D-glucopyranoside Natural products OCC1CC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4ccc(O)c(O)c4)C(O)C(O)C1O NBSPOAXOBIRHSH-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
【0001】0001
【産業上の利用分野】本発明はカルシウム拮抗活性を有
し、医薬品として有用なフェノール化合物に関するもの
である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to phenolic compounds having calcium antagonistic activity and useful as pharmaceuticals.
【0002】0002
【従来の技術】カルシウムは、生体において筋収縮や細
胞運動などの調節因子として重要な役割を担っている。
カルシウム拮抗剤は心筋や平滑筋に作用して細胞外から
のカルシウムの流入を抑制し、血管平滑筋などの弛緩を
引き起こし、血流改善や血圧降下が見られる。よってカ
ルシウム拮抗剤は、臨床において治療薬として高血圧、
狭心症、不整脈、脳循環障害など心血管系疾患に適用さ
れており、今後高齢化社会を迎えるにあたりますます重
要性を増すと考えられる。BACKGROUND OF THE INVENTION Calcium plays an important role in living organisms as a regulating factor for muscle contraction and cell movement. Calcium antagonists act on myocardium and smooth muscles, suppressing the influx of calcium from outside the cells, causing relaxation of vascular smooth muscles, and improving blood flow and lowering blood pressure. Therefore, calcium channel blockers are used clinically as therapeutic agents for hypertension,
It has been applied to cardiovascular diseases such as angina pectoris, arrhythmia, and cerebral circulation disorders, and is expected to become increasingly important as we enter an aging society.
【0003】0003
【発明が解決しようとする課題】そこで、これら循環器
系障害の治療、ないしは予防を考えた場合、新しいタイ
プのカルシウム拮抗剤の開発が望まれていた。[Problems to be Solved by the Invention] Therefore, when considering the treatment or prevention of these circulatory system disorders, it has been desired to develop a new type of calcium antagonist.
【0004】本発明者等は、循環器系疾患の治療に有効
なカルシウム拮抗作用を有する化合物を求めて鋭意研究
を重ねた結果、生薬ケイガイ[Schizonepet
a tenuifolia Briq.、シソ科(
Labiatae)]の花穂に含まれるフェノール化合
物類がカルシウム拮抗作用を有することを見いだし、本
発明を完成させた。[0004] As a result of extensive research in search of a compound with calcium antagonistic action that is effective for the treatment of circulatory system diseases, the present inventors discovered the crude drug Schizonepet.
a tenuifolia Briq. , Lamiaceae (
The present invention has been completed based on the discovery that phenolic compounds contained in the flower spikes of the genus Labiatae) have a calcium antagonistic effect.
【0005】すなわち本発明は、下記式I(式I中、R
はルチノースを意味する。)、下記式II(式II中、
R1およびR2は、同じにまたは異なって水素原子また
はグルコースを示す。)、下記式III、下記式IV
(式IV中、R3は水素原子またはメチル基を示す。)
または下記式V
で表される化合物を有効成分とするカルシウム拮抗剤で
ある。That is, the present invention provides the following formula I (in formula I, R
means rutinose. ), the following formula II (in formula II,
R1 and R2 are the same or different and represent a hydrogen atom or glucose. ), the following formula III, the following formula IV (in formula IV, R3 represents a hydrogen atom or a methyl group)
Alternatively, it is a calcium antagonist containing a compound represented by the following formula V as an active ingredient.
【0006】以下、式I、II、III、IVおよびV
で表される化合物をまとめて式の化合物という。Below, formulas I, II, III, IV and V
The compounds represented by are collectively referred to as compounds of the formula.
【0007】式の化合物を得るには例えば、次のような
方法が挙げられる。For example, the following methods can be used to obtain the compound of the formula.
【0008】ケイガイの花穂を水、アルコール類、水と
アルコール類の混合溶媒または水とアセトンの混合溶媒
で抽出し、該抽出液から溶媒を除去した残渣をそのまま
、または必要に応じて水に溶解し、石油エーテル、エー
テル、クロロホルムなどの有機溶媒で抽出し、得られた
有機溶媒に移行する脂溶性成分を除去した後、水、メタ
ノール、エタノール、酢酸、クロロホルム、酢酸エチル
、n−ヘキサン、アセトン、ベンゼンから選ばれる少な
くとも一つを溶出溶媒としてダイヤイオンHP−20、
MCIゲルCHP20P等のポーラスポリマー、セファ
デックスLH−20等のセファデックス、逆相系シリカ
ゲル、シリカゲル、ポリアミド、活性炭またはセルロー
ス等を担体に用いたカラムクロマトグラフィーに数回付
し、薄層クロマトグラフィーで目的成分を確認しながら
分画することにより得ることができる。場合によりメタ
ノール、エタノール等の適当な溶媒を用いて再結晶する
ことにより精製してもよい。[0008] The flower spikes of Physcomitrella sinensis are extracted with water, alcohol, a mixed solvent of water and alcohols, or a mixed solvent of water and acetone, and the residue obtained by removing the solvent from the extract can be used as is or dissolved in water as necessary. After extraction with an organic solvent such as petroleum ether, ether, or chloroform to remove fat-soluble components that migrate to the resulting organic solvent, extract with water, methanol, ethanol, acetic acid, chloroform, ethyl acetate, n-hexane, or acetone. , Diaion HP-20 using at least one selected from benzene as an elution solvent,
It was subjected to column chromatography several times using porous polymers such as MCI gel CHP20P, Sephadex such as Sephadex LH-20, reversed-phase silica gel, silica gel, polyamide, activated carbon, cellulose, etc. as a carrier, and then subjected to thin layer chromatography several times. It can be obtained by fractionating while checking the target component. In some cases, the product may be purified by recrystallization using a suitable solvent such as methanol or ethanol.
【0009】次に、式の化合物の製造の具体例を示す。Next, a specific example of the production of the compound of the formula will be shown.
【0010】具体例1
ケイガイの花穂9.9kgをメタノール36lで抽出し
、得られた抽出液から溶媒を減圧下留去しメタノールエ
キスを得た。このメタノールエキスを水−メタノールに
溶解し、クロロホルムで抽出して得られた脂溶性成分を
除去した後、ダイヤイオンHP−20(三菱化成製、以
下同じ)カラムクロマトグラフィーに付し、水6l、5
0%メタノール−水10l、次いで100%メタノール
10lで溶出した。Concrete Example 1 9.9 kg of flower spikes of A. japonica were extracted with 36 liters of methanol, and the solvent was distilled off from the resulting extract under reduced pressure to obtain a methanol extract. This methanol extract was dissolved in water-methanol, extracted with chloroform to remove the obtained fat-soluble components, and then subjected to Diaion HP-20 (manufactured by Mitsubishi Kasei, hereinafter the same) column chromatography. 5
Elution was performed with 10 liters of 0% methanol-water and then 10 liters of 100% methanol.
【0011】50%メタノール−水および100%メタ
ノール溶出部は、溶媒を減圧下留去し、それぞれ50%
メタノール−水溶出画分78.2gおよび100%メタ
ノール溶出画分50.5gを得た。[0011] The 50% methanol-water and 100% methanol eluates were separated by distillation of the solvent under reduced pressure.
78.2 g of methanol-water eluted fraction and 50.5 g of 100% methanol eluted fraction were obtained.
【0012】この50%メタノール−水溶出画分をセフ
ァデックスLH−20(ファルマシア製、以下同じ)カ
ラムクロマトグラフィーに付し、水から始めて順次エタ
ノール含量を増やして溶出し、50%エタノール−水溶
出画分10.5gおよび100%エタノール溶出画分7
.3gを得た。[0012] This 50% methanol-water elution fraction was subjected to Sephadex LH-20 (manufactured by Pharmacia, hereinafter the same) column chromatography, starting with water and eluting with increasing ethanol content sequentially, and 50% ethanol-water elution. Fraction 10.5g and 100% ethanol elution fraction 7
.. 3g was obtained.
【0013】次にこれらの画分をそれぞれポーラスポリ
マーであるMCIゲルCHP20P(三菱化成製、以下
同じ)を用いたカラムクロマトグラフィーに付し、水か
ら順次メタノール含量を増やして溶出し、50%エタノ
ール−水溶出画分より画分AおよびB、100%エタノ
ール溶出画分より画分CおよびDを得た。Next, each of these fractions was subjected to column chromatography using a porous polymer, MCI gel CHP20P (manufactured by Mitsubishi Kasei, hereinafter the same), and eluted with increasing methanol content sequentially starting with water, and 50% ethanol. - Fractions A and B were obtained from the water elution fraction, and fractions C and D were obtained from the 100% ethanol elution fraction.
【0014】ダイヤイオンHP−20カラムクロマトグ
ラフィー100%メタノール溶出画分を、セファデック
スLH−20カラムクロマトグラフィーに付し、水から
始めて順次エタノール含量を増やして溶出し、25%エ
タノール−水溶出画分2.4g、50%エタノール−水
溶出画分6.9g、75%エタノール−水溶出画分6.
7gおよび100%エタノール溶出画分3.7gを得た
。The 100% methanol elution fraction of the Diaion HP-20 column chromatography was applied to the Sephadex LH-20 column chromatography, and elution was carried out by sequentially increasing the ethanol content starting with water, resulting in a 25% ethanol-water elution fraction. 2.4 g, 50% ethanol-water elution fraction 6.9 g, 75% ethanol-water elution fraction 6.
7 g and 3.7 g of 100% ethanol elution fraction were obtained.
【0015】次にこれらの画分をそれぞれMCIゲルC
HP20Pを用いたカラムクロマトグラフィーに付し、
水から順次メタノール含量を増やして溶出し、25%エ
タノール−水溶出画分より画分E、75%エタノール−
水溶出画分より画分F、100%エタノール溶出画分よ
り画分Gを得た。Next, each of these fractions was subjected to MCI gel C.
Subjected to column chromatography using HP20P,
Elute with increasing methanol content sequentially starting with water, and fraction E is obtained from the 25% ethanol-water elution fraction, and 75% ethanol-
Fraction F was obtained from the water elution fraction, and Fraction G was obtained from the 100% ethanol elution fraction.
【0016】画分Cをさらに高速液体クロマトグラフィ
ー(分配吸着クロマトグラフィー用充填カラム;TSK
gel ODS−80TM、東ソー製、以下同じ
)に付し、40%メタノール−水で溶出し、白色無晶形
粉末186mgを得た。この白色無晶形粉末の理化学的
性質は以下のごとくであり、これらのデータより式Iの
化合物であるヘスペリジン(hesperidin)と
構造を決定した。Fraction C was further subjected to high performance liquid chromatography (packed column for partition adsorption chromatography; TSK
gel ODS-80TM (manufactured by Tosoh, same hereinafter) and eluted with 40% methanol-water to obtain 186 mg of white amorphous powder. The physicochemical properties of this white amorphous powder are as follows, and from these data, the structure was determined to be hesperidin, a compound of formula I.
【0017】マススペクトルFAB−MS m/z:
611[MH]+13C−核磁気共鳴スペクトル(δ
ppm in DMSO−d6):17.7(q
),42.0(t),55.6(q),66.0(t)
,68.2(d),69.5(d),70.2(d),
70.6(d),72.0(d),72.9(d),7
5.5(d),76.2(d),78.3(d),95
.5(d),96.3(d),99.4(d),100
.5(d),103.3(s),111.9(d),1
14.0(d),117.8(d),130.8(s)
,146.4(s),147.9(s),162.4(
s),163.0(s),165.1(s),196.
8(s)Mass spectrum FAB-MS m/z:
611[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in DMSO-d6): 17.7(q
), 42.0 (t), 55.6 (q), 66.0 (t)
, 68.2(d), 69.5(d), 70.2(d),
70.6(d), 72.0(d), 72.9(d), 7
5.5(d), 76.2(d), 78.3(d), 95
.. 5(d), 96.3(d), 99.4(d), 100
.. 5(d), 103.3(s), 111.9(d), 1
14.0(d), 117.8(d), 130.8(s)
, 146.4 (s), 147.9 (s), 162.4 (
s), 163.0 (s), 165.1 (s), 196.
8(s)
【0018】具体例2
具体例1の画分Fをさらに高速液体クロマトグラフィー
に付し、45%メタノール−水で溶出し、黄色無晶形粉
末47mgを得た。この黄色無晶形粉末の理化学的性質
は以下のごとくであり、これらのデータより式II中R
1およびR2がいずれも水素原子の化合物であるルテオ
リン(luteolin)と構造を決定した。Specific Example 2 Fraction F of Specific Example 1 was further subjected to high performance liquid chromatography and eluted with 45% methanol-water to obtain 47 mg of yellow amorphous powder. The physical and chemical properties of this yellow amorphous powder are as follows, and from these data, R in formula II
The structure was determined to be luteolin, a compound in which both 1 and R2 are hydrogen atoms.
【0019】マススペクトルFAB−MS m/z:
287[MH]+13C−核磁気共鳴スペクトル(δ
ppm in DMSO−d6):94.2(d
),99.2(d),103.3(d),104.2(
s),113.8(d),116.4(d),119.
3(d),122.1(s),146.2(s),15
0.1(s),157.9(s),162.1(s),
164.5(s),164.7(s),182.2(s
)Mass spectrum FAB-MS m/z:
287[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in DMSO-d6):94.2(d
), 99.2(d), 103.3(d), 104.2(
s), 113.8(d), 116.4(d), 119.
3(d), 122.1(s), 146.2(s), 15
0.1(s), 157.9(s), 162.1(s),
164.5 (s), 164.7 (s), 182.2 (s
)
【0020】具体例3
具体例1の画分Aをさらに高速液体クロマトグラフィー
に付し、40%メタノール−水で溶出し、淡黄色無晶形
粉末175mgを得た。この淡黄色無晶形粉末の理化学
的性質は以下のごとくであり、これらのデータより式I
I中R1がグルコース、R2が水素原子の化合物である
ルテオリン 7−O−β−D−グルコピラノシド(l
uteolin 7−O−β−D−glucopyr
anoside)と構造を決定した。Specific Example 3 Fraction A of Specific Example 1 was further subjected to high performance liquid chromatography and eluted with 40% methanol-water to obtain 175 mg of a pale yellow amorphous powder. The physicochemical properties of this pale yellow amorphous powder are as follows, and from these data, formula I
Luteolin 7-O-β-D-glucopyranoside (l), which is a compound in which R1 is glucose and R2 is hydrogen atom,
uteolin 7-O-β-D-glucopyr
anoside) and its structure was determined.
【0021】マススペクトルFAB−MS m/z:
449[MH]+13C−核磁気共鳴スペクトル(δ
ppm in DMSO−d6):60.7(t
),69.6(d),73.1(d),76.4(d)
,77.2(d),94.7(d),99.5(d),
100.0(d),103.2(d),105.4(s
),113.5(d),116.0(d),119.1
(d),121.4(s),145.8(s),149
.9(s),157.0(s),161.2(s),1
62.9(s),164.5(s),181.9(s)
Mass spectrum FAB-MS m/z:
449[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in DMSO-d6): 60.7(t
), 69.6(d), 73.1(d), 76.4(d)
, 77.2(d), 94.7(d), 99.5(d),
100.0(d), 103.2(d), 105.4(s
), 113.5(d), 116.0(d), 119.1
(d), 121.4 (s), 145.8 (s), 149
.. 9(s), 157.0(s), 161.2(s), 1
62.9(s), 164.5(s), 181.9(s)
【0022】具体例4
具体例1の画分Bをさらに高速液体クロマトグラフィー
に付し、40%メタノール−水で溶出し、黄色針状晶4
73mgを得た。この黄色針状晶の理化学的性質は以下
のごとくであり、これらのデータより式IIIの化合物
であるカフェイック アシッド(caffeic
acid)と構造を決定した。Specific Example 4 Fraction B of Specific Example 1 was further subjected to high performance liquid chromatography, eluted with 40% methanol-water, and yellow needle-like crystals 4 were obtained.
73 mg was obtained. The physicochemical properties of this yellow needle-like crystal are as follows. From these data, it has been determined that caffeic acid, which is a compound of formula III.
acid) and its structure was determined.
【0023】マススペクトルFAB−MS m/z:
181[MH]+13C−核磁気共鳴スペクトル(δ
ppm in CD3OD):115.1(d)
,115.5(d),116.5(d),122.8(
d),127.8(d),146.8(s),147.
0(d),149.4(s),171.1(s)Mass spectrum FAB-MS m/z:
181[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in CD3OD): 115.1(d)
, 115.5(d), 116.5(d), 122.8(
d), 127.8(d), 146.8(s), 147.
0(d), 149.4(s), 171.1(s)
【00
24】具体例5
具体例1の画分Dをさらに高速液体クロマトグラフィー
に付し、50%メタノール−水で溶出し、無色無晶形粉
末1.61gを得た。この無色無晶形粉末の理化学的性
質は以下の如くであり、これらのデータより式IV中R
3が水素原子の化合物であるロスマリニックアシッド(
rosmarinic acid)と構造を決定した
。00
[24] Specific Example 5 Fraction D of Specific Example 1 was further subjected to high performance liquid chromatography and eluted with 50% methanol-water to obtain 1.61 g of colorless amorphous powder. The physical and chemical properties of this colorless amorphous powder are as follows, and from these data, R in formula IV
Rosmarinic acid, which is a compound where 3 is a hydrogen atom (
rosmarinic acid) and its structure was determined.
【0025】マススペクトルFAB−MS m/z:
361[MH]+13C−核磁気共鳴スペクトル(δ
ppm in CD3OD):38.0(t),
74.9(d),114.5(d),115.3(d)
,116.3(d),116.5(d),117.6(
d),121.9(d),123.2(d),127.
7(s),129.4(s),145.2(s),14
6.1(s),146.8(s),147.7(d),
149.7(s),168.5(s),174.0(s
)Mass spectrum FAB-MS m/z:
361[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in CD3OD): 38.0(t),
74.9(d), 114.5(d), 115.3(d)
, 116.3(d), 116.5(d), 117.6(
d), 121.9(d), 123.2(d), 127.
7(s), 129.4(s), 145.2(s), 14
6.1(s), 146.8(s), 147.7(d),
149.7 (s), 168.5 (s), 174.0 (s
)
【0026】具体例6
具体例1の画分Eをさらに高速液体クロマトグラフィー
に付し、55%メタノールー水で溶出し、無色無晶形粉
末28mgを得た。この無色無晶形粉末の理化学的性質
は以下のごとくであり、これらのデータより式IV中R
3がメチル基の化合物であるロスマリニックアシッドモ
ノメチルエステル(rosmarinic acid
monomethylester)と構造を決定し
た。Specific Example 6 Fraction E of Specific Example 1 was further subjected to high performance liquid chromatography and eluted with 55% methanol-water to obtain 28 mg of colorless amorphous powder. The physical and chemical properties of this colorless amorphous powder are as follows, and from these data, R in formula IV
Rosmarinic acid monomethyl ester (rosmarinic acid monomethyl ester), which is a compound in which 3 is a methyl group
monomethylester) and its structure was determined.
【0027】マススペクトルFAB−MS m/z:
375[MH]+13C−核磁気共鳴スペクトル(δ
ppm in CD3OD):20.8(q),
38.0(t),74.9(d),114.5(d),
115.3(d),116.3(d),116.5(d
),117.6(d),121.9(d),123.2
(d),127.7(s),129.4(s),145
.2(s),146.1(s),146.8(s),1
47.7(d),149.7(s),168.5(s)
,174.0(s)Mass spectrum FAB-MS m/z:
375[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in CD3OD): 20.8 (q),
38.0(t), 74.9(d), 114.5(d),
115.3(d), 116.3(d), 116.5(d
), 117.6(d), 121.9(d), 123.2
(d), 127.7 (s), 129.4 (s), 145
.. 2(s), 146.1(s), 146.8(s), 1
47.7(d), 149.7(s), 168.5(s)
,174.0(s)
【0028】具体例7
具体例1の画分Gをさらに高速液体クロマトグラフィー
に付し、55%メタノール−水で溶出し、無色無晶形粉
末573mgを得た。この無色無晶形粉末の理化学的性
質は以下のごとくであり、これらのデータより式Vの化
合物であるシゾテヌインA(schizotenuin
A)と構造を決定した。Specific Example 7 Fraction G of Specific Example 1 was further subjected to high performance liquid chromatography and eluted with 55% methanol-water to obtain 573 mg of colorless amorphous powder. The physicochemical properties of this colorless amorphous powder are as follows, and based on these data, it has been determined that schizotenuin A (schizotenuin A), which is a compound of formula V.
A) and the structure were determined.
【0029】マススペクトルFAB−MS m/z:
717[MH]+13C−核磁気共鳴スペクトル(δ
ppm in CD3OD):37.7(t),
37.9(d),74.8(d),74.9(d),1
08.1(s),111.0(d),116.1(d)
,116.3(d),116.4(d),116.6(
d),116.9(d),117.2(d),117.
6(d),117.6(d),121.9(s),12
2.0(d),122.1(d),123.5(d),
129.1(s),129.2(s),130.6(s
),132.6(s),143.6(s),145.0
(s),145.1(s),145.2(s),45.
9(s),146.0(s),146.2(s),14
8.0(d),149.3(s),163.7(s),
164.9(s),168.2(s),173.4(s
),173.6(s)Mass spectrum FAB-MS m/z:
717[MH]+13C-nuclear magnetic resonance spectrum (δ
ppm in CD3OD): 37.7(t),
37.9(d), 74.8(d), 74.9(d), 1
08.1(s), 111.0(d), 116.1(d)
, 116.3(d), 116.4(d), 116.6(
d), 116.9(d), 117.2(d), 117.
6(d), 117.6(d), 121.9(s), 12
2.0(d), 122.1(d), 123.5(d),
129.1 (s), 129.2 (s), 130.6 (s
), 132.6 (s), 143.6 (s), 145.0
(s), 145.1 (s), 145.2 (s), 45.
9(s), 146.0(s), 146.2(s), 14
8.0(d), 149.3(s), 163.7(s),
164.9 (s), 168.2 (s), 173.4 (s
), 173.6(s)
【0030】次に、式の化合物がカルシウムチャンネル
におけるニトレンジピン結合阻害作用を有し、カルシウ
ム拮抗剤として循環器疾患の治療に有効であることにつ
いて実験例を挙げて説明する。Next, the fact that the compound of the formula has an inhibitory effect on nitrendipine binding in calcium channels and is effective as a calcium antagonist in the treatment of cardiovascular diseases will be explained with reference to experimental examples.
【0031】実験例
<ウサギ骨格筋膜蛋白の調整>11週齢の日本白色ウサ
ギ(Healthy)左後肢大腿部より骨格筋を摘出し
た後、ハサミで切断した。これに10倍量の50mMト
リス塩酸緩衝液(pH7.4)を加えホモジナイズし、
5,000×gで20分間遠心した。この上清を再び4
5,000×gで30分間遠沈し、その沈渣を更に45
,000×gで30分間遠沈した。この沈渣を膜蛋白濃
度が1mg/mlとなるよう50mMトリス塩酸緩衝液
に再懸濁し、以下の実験に供した。なお、以上の実験操
作は全て4℃で行った。Experimental Example <Preparation of Rabbit Skeletal Muscle Protein> Skeletal muscle was extracted from the left hind thigh of an 11-week-old Japanese white rabbit (Healthy) and then cut with scissors. Add 10 times the volume of 50mM Tris-HCl buffer (pH 7.4) to this and homogenize.
Centrifugation was performed at 5,000×g for 20 minutes. Add this supernatant again to
Centrifuge at 5,000 x g for 30 minutes, and centrifuge the precipitate for 45 minutes.
,000×g for 30 minutes. This precipitate was resuspended in 50 mM Tris-HCl buffer so that the membrane protein concentration was 1 mg/ml, and used in the following experiment. Note that all of the above experimental operations were performed at 4°C.
【0032】<[3H]ニトレンジピンバインディング
アッセイ>試験管に、50mMトリス塩酸緩衝液(pH
7.4)880μl、ウサギ骨格筋膜蛋白(1mg/m
l)100μl、式の化合物の溶液10μl、[3H]
ニトレンジピン10μl(3.7kBq)をとり、25
℃で1時間インキュベートした。反応終了後、ホワット
マン(Whatmann)GF/Bフィルターで吸引濾
過し、フィルターを5mlの氷冷50mMトリス緩衝液
で2回吸引、液体シンチレーター3mlを加えた。1時
間放置後、液体シンチレーションカウンターにて放射能
を測定した。<[3H]Nitrendipine binding assay> In a test tube, add 50mM Tris-HCl buffer (pH
7.4) 880 μl, rabbit skeletal muscle protein (1 mg/m
l) 100 μl, 10 μl solution of compound of formula, [3H]
Take 10 μl (3.7 kBq) of nitrendipine and add 25
Incubated for 1 hour at °C. After the reaction was completed, the mixture was suction-filtered using a Whatmann GF/B filter, the filter was suctioned twice with 5 ml of ice-cold 50 mM Tris buffer, and 3 ml of liquid scintillator was added. After standing for 1 hour, radioactivity was measured using a liquid scintillation counter.
【0033】阻害率は次式より算出した。
A:式の化合物を含まない場合の放射能B:式の化合物
を添加した場合の放射能上記に基づき、具体例で得た化
合物の10μMでのニトレンジピンの結合阻害率(%)
とIC50を表1に示す。The inhibition rate was calculated using the following formula. A: Radioactivity when the compound of the formula is not included B: Radioactivity when the compound of the formula is added Based on the above, binding inhibition rate of nitrendipine at 10 μM of the compound obtained in the specific example (%)
and IC50 are shown in Table 1.
【0034】表1Table 1
【0035】表1より式の化合物のカルシウム拮抗作用
が確認された。From Table 1, the calcium antagonistic effect of the compound of the formula was confirmed.
【0036】次に式の化合物の急性毒性試験をICR系
マウスを用いて行ったところ、具体例1〜7で得た化合
物は2g/kgの経口投与で死亡例はなく、式の化合物
は極めて毒性が低く、安全性の高いものであることが確
認された。[0036] Next, an acute toxicity test of the compound of the formula was conducted using ICR mice, and the compounds obtained in Examples 1 to 7 caused no death when administered orally at a dose of 2 g/kg. It was confirmed that the toxicity is low and the safety is high.
【0037】次に、式の化合物の投与量および製剤化に
ついて説明する。Next, the dosage and formulation of the compound of the formula will be explained.
【0038】式の化合物はそのまま、あるいは慣用の製
剤担体と共に動物および人に投与することができる。投
与形態としては、特に限定がなく、必要に応じ適宜選択
して使用され、錠剤、カプセル剤、顆粒剤、細粒剤、散
剤等の経口剤、注射剤、坐剤等の非経口剤が挙げられる
。The compounds of the formula can be administered to animals and humans either neat or with conventional pharmaceutical carriers. The dosage form is not particularly limited and may be selected and used as necessary, and may include oral dosage forms such as tablets, capsules, granules, fine granules, and powders, and parenteral dosage forms such as injections and suppositories. It will be done.
【0039】経口剤として所期の効果を発揮するために
は、患者の年令、体重、疾患の程度により異なるが、通
常成人で式の化合物の重量として30mg〜3gを1日
数回に分けての服用が適当と思われる。In order to exert the desired effect as an oral agent, although it varies depending on the age, weight, and severity of the disease of the patient, it is usual for adults to take 30 mg to 3 g of the compound of the formula in divided doses several times a day. It seems appropriate to take .
【0040】経口剤は、例えばデンプン、乳糖、白糖、
マンニット、カルボキシメチルセルロース、コーンスタ
ーチ、無機塩類等を用いて常法に従って製造される。[0040] Oral preparations include, for example, starch, lactose, sucrose,
It is manufactured using conventional methods using mannitol, carboxymethyl cellulose, cornstarch, inorganic salts, etc.
【0041】この種の製剤には、適宜前記賦形剤の他に
、結合剤、崩壊剤、界面活性剤、滑沢剤、流動性促進剤
、矯味剤、着色剤、香料等を使用することができる。
それぞれの具体例は以下に示すごとくである。[0041] In addition to the excipients mentioned above, binders, disintegrants, surfactants, lubricants, fluidity promoters, flavoring agents, coloring agents, fragrances, etc. may be used in this type of preparation as appropriate. Can be done. Specific examples of each are shown below.
【0042】[結合剤]デンプン、デキストリン、アラ
ビアゴム末、ゼラチン、ヒドロキシプロピルスターチ、
メチルセルロース、カルボキシメチルセルロースナトリ
ウム、ヒドロキシプロピルセルロース、結晶セルロース
、エチルセルロース、ポリビニルピロリドン、マクロゴ
ール。[Binder] Starch, dextrin, gum arabic powder, gelatin, hydroxypropyl starch,
Methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone, macrogol.
【0043】[崩壊剤]デンプン、ヒドロキシプロピル
スターチ、カルボキシメチルセルロースナトリウム、カ
ルボキシメチルセルロースカルシウム、カルボキシメチ
ルセルロース、低置換ヒドロキシプロピルセルロース。[Disintegrant] Starch, hydroxypropyl starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, low substituted hydroxypropyl cellulose.
【0044】[界面活性剤]ラウリル硫酸ナトリウム、
大豆レシチン、ショ糖脂肪酸エステル、ポリソルベート
80。[Surfactant] Sodium lauryl sulfate,
Soy lecithin, sucrose fatty acid ester, polysorbate 80.
【0045】[滑沢剤]タルク、ロウ類、水素添加植物
油、ショ糖脂肪酸エステル、ステアリン酸マグネシウム
、ステアリン酸カルシウム、ステアリン酸アルミニウム
、ポリエチレングリコール。[Lubricant] Talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, polyethylene glycol.
【0046】[流動性促進剤]軽質無水ケイ酸、乾燥水
酸化アルミニウムゲル、合成ケイ酸アルミニウム、ケイ
酸マグネシウム。[Fluidity promoter] Light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate.
【0047】また、式の化合物は、懸濁液、エマルジョ
ン剤、シロップ剤、エリキシル剤としても投与すること
ができ、これらの各種剤形には、矯味矯臭剤、着色剤を
含有してもよい。The compounds of the formula can also be administered as suspensions, emulsions, syrups, and elixirs, and these various dosage forms may contain flavorings and coloring agents. .
【0048】非経口剤として所期の効果を発揮するため
には、患者の年令、体重、疾患の程度により異なるが、
通常成人で式の化合物の重量として1日5〜500mg
までの静注、点滴静注、皮下注射、筋肉注射が適当と思
われる。In order to exert the desired effect as a parenteral agent, it depends on the age, weight, and severity of the disease of the patient;
Normally for an adult, 5 to 500 mg per day by weight of the compound of formula
Intravenous injection, intravenous drip, subcutaneous injection, and intramuscular injection are considered appropriate.
【0049】この非経口剤は常法に従って製造され、希
釈剤として一般に注射用蒸留水、生理食塩水、ブドウ糖
水溶液、注射用植物油、ゴマ油、ラッカセイ油、ダイズ
油、トウモロコシ油、プロピレングリコール、ポリエチ
レングリコール等を用いることができる。さらに必要に
応じて、殺菌剤、防腐剤、安定剤を加えてもよい。また
、この非経口剤は安定性の点から、バイアル等に充填後
冷凍し、通常の凍結乾燥技術により水分を除去し、使用
直前に凍結乾燥物から液剤を再調製することもできる。
さらに、必要に応じて適宜、等張化剤、安定剤、防腐剤
、無痛化剤等を加えても良い。This parenteral preparation is manufactured according to a conventional method, and diluents generally include distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, and polyethylene glycol. etc. can be used. Furthermore, a bactericide, a preservative, and a stabilizer may be added as necessary. In addition, from the viewpoint of stability, this parenteral preparation may be filled into a vial or the like, then frozen, water removed by ordinary freeze-drying techniques, and a liquid preparation prepared from the freeze-dried product immediately before use. Furthermore, isotonizing agents, stabilizers, preservatives, soothing agents, etc. may be added as appropriate.
【0050】その他の非経口剤としては、外用液剤、軟
膏等の塗布剤、直腸内投与のための坐剤等が挙げられ、
常法に従って製造される。Other parenteral preparations include liquid preparations for external use, liniments such as ointments, suppositories for intrarectal administration, etc.
Manufactured according to conventional methods.
【0051】次に実施例を示して本発明をさらに詳細に
説明するが、本発明はこれによりなんら制限されるもの
ではない。[0051] Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto in any way.
【0052】実施例1
■コーンスターチ 44g■結
晶セルロース 40g■カルボ
キシメチル
セルロースカルシウム 5g■軽質無水ケイ
酸 0.5g■ステアリン酸マ
グネシウム 0.5g■具体例1で得た化合物
10g計 100g
上記の処方に従って■〜■を均一に混合し、打錠機にて
圧縮成型して一錠200mgの錠剤を得た。この錠剤一
錠には、具体例1で得た化合物20mgが含有されてお
り、成人1日5〜15錠を数回にわけて服用する。Example 1 ■ Corn starch 44 g ■ Crystalline cellulose 40 g ■ Carboxymethyl cellulose calcium 5 g ■ Light anhydrous silicic acid 0.5 g ■ Magnesium stearate 0.5 g ■ Compound obtained in Specific Example 1
10g total 100g According to the above recipe, ① to ③ were mixed uniformly and compressed using a tablet machine to obtain tablets each weighing 200 mg. One tablet contains 20 mg of the compound obtained in Example 1, and adults should take 5 to 15 tablets a day in several doses.
【0053】実施例2
■結晶セルロース 84.5g■ス
テアリン酸マグネシウム 0.5g■カルボキシメチ
ル
セルロースカルシウム 5g■具体例2
で得た化合物 10g計 100
g
上記の処方に従って■、■および■の一部を均一に混合
し、圧縮成型した後、粉砕し、■および■の残量を加え
て混合し、打錠機にて圧縮成型して一錠200mgの錠
剤を得た。この錠剤一錠には、具体例2で得た化合物2
0mgが含有されており、成人1日5〜15錠を数回に
わけて服用する。Example 2 ■ Crystalline cellulose 84.5 g ■ Magnesium stearate 0.5 g ■ Carboxymethyl cellulose calcium 5 g ■ Specific example 2
Compound obtained in 10g total 100
g According to the above recipe, mix ■, ■, and part of ■ uniformly, compression mold, crush, add remaining amounts of ■ and ■, mix, and compress and mold with a tablet machine to make one tablet. 200 mg tablets were obtained. One tablet of this tablet contains compound 2 obtained in specific example 2.
It contains 0mg, and adults should take 5 to 15 tablets a day in several doses.
【0054】実施例3
■結晶セルロース 49.5g■1
0%ヒドロキシプロピル
セルロースエタノール溶液 35g
■カルボキシメチル
セルロースカルシウム 5g■ステアリン酸
マグネシウム 0.5g■具体例3で得た化合物
10g計 100g
上記の処方に従って■、■および■を均一に混合し、常
法によりねつ和し、押し出し造粒機により造粒し、乾燥
・解砕した後、■および■を混合し、打錠機にて圧縮成
型して一錠200mgの錠剤を得た。この錠剤一錠には
、具体例3で得た化合物20mgが含有されており、成
人1日5〜15錠を数回にわけて服用する。Example 3 ■Crystalline cellulose 49.5g■1
0% hydroxypropylcellulose ethanol solution 35g ■ Carboxymethylcellulose calcium 5g ■ Magnesium stearate 0.5g ■ Compound obtained in Specific Example 3
10g Total: 100g Mix ■, ■, and ■ uniformly according to the above recipe, net by a conventional method, granulate with an extrusion granulator, dry and crush, mix ■ and ■, and pound. Compression molding was performed using a tablet machine to obtain tablets each weighing 200 mg. One tablet contains 20 mg of the compound obtained in Example 3, and adults should take 5 to 15 tablets a day in several doses.
【0055】実施例4
■コーンスターチ 34.5g■ス
テアリン酸マグネシウム 50g■カルボキシメチル
セルロースカルシウム 5g■軽質無水ケイ
酸 0.5g■具体例4で得た化合
物 10g計 100g
上記の処方に従って■〜■を均一に混合し、圧縮成型機
にて圧縮成型後、破砕機により粉砕し、篩別して顆粒剤
を得た。この顆粒剤1gには、具体例4で得た化合物1
00mgが含有されており、成人1日1〜3gを数回に
わけて服用する。Example 4 ■ Corn starch 34.5 g ■ Magnesium stearate 50 g ■ Carboxymethyl cellulose calcium 5 g ■ Light anhydrous silicic acid 0.5 g ■ Compound obtained in Example 4 10 g Total 100 g Mix ■ to ■ uniformly according to the above recipe The mixture was mixed, compression molded using a compression molding machine, pulverized using a crusher, and sieved to obtain granules. 1 g of this granule contains compound 1 obtained in specific example 4.
It contains 00 mg, and adults should take 1 to 3 g per day in several doses.
【0056】実施例5
■結晶セルロース 55g■1
0%ヒドロキシプロピル
セルロースエタノール溶液35g
■具体例5で得た化合物 10g計
100g
上記の処方に従って■〜■を均一に混合し、ねつ和した
。押し出し造粒機により造粒後、乾燥し、篩別して顆粒
剤を得た。この顆粒剤1gには、具体例5で得た化合物
100mgが含有されており、成人1日1〜3gを数回
にわけて服用する。Example 5 ■Crystalline cellulose 55g■1
0% hydroxypropylcellulose ethanol solution 35g ■ Compound obtained in Example 5 10g total
100g According to the above recipe, ① to ② were uniformly mixed and made into a paste. After granulation using an extrusion granulator, the mixture was dried and sieved to obtain granules. 1 g of this granule contains 100 mg of the compound obtained in Example 5, and adults should take 1 to 3 g per day in several doses.
【0057】実施例6
■コーンスターチ 89.5g■軽質無
水ケイ酸 0.5g■具体例6で得
た化合物 10g計 100g
上記の処方に従って■〜■を均一に混合し、200mg
を2号カプセルに充填した。このカプセル剤1カプセル
には、具体例6で得た化合物20mgが含有されており
、成人1日5〜15カプセルを数回にわけて服用する。Example 6 ■ Corn starch 89.5 g ■ Light anhydrous silicic acid 0.5 g ■ Compound obtained in Example 6 10 g Total 100 g Mix ■ to ■ uniformly according to the above recipe, and give 200 mg
was filled into a No. 2 capsule. One capsule of this preparation contains 20 mg of the compound obtained in Example 6, and adults should take 5 to 15 capsules a day in several doses.
【0058】実施例7
■大豆油
5g■注射用蒸留水 89.
5g■大豆リン脂質 2.5g
■グリセリン 2
g■具体例7で得た化合物 1g全量
100g上記の処方に従っ
て■を■および■に溶解し、これに■と■の溶液を加え
て乳化し、注射剤を得た。Example 7 ■ Soybean oil
5g ■ Distilled water for injection 89.
5g■ Soybean phospholipid 2.5g
■Glycerin 2
g■Compound obtained in specific example 7 1g total amount
100g of ■ was dissolved in ■ and ■ according to the above recipe, and the solutions of ■ and ■ were added to emulsify to obtain an injection.
Claims (5)
合物を有効成分とするカルシウム拮抗剤。1. A calcium antagonist comprising a compound represented by the following formula I (in formula I, R means rutinose) as an active ingredient.
水素原子またはグルコースを示す。)[Claim 2] The following formula II (In formula II, R1 and R2 are the same or different and represent a hydrogen atom or glucose.)
で表される化合物を有効成分とするカルシウム拮抗剤。[Claim 4] The following formula IV (In formula IV, R3 represents a hydrogen atom or a methyl group.)
A calcium antagonist whose active ingredient is a compound represented by
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3022643A JPH04243822A (en) | 1991-01-24 | 1991-01-24 | Calcium antagonist |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3022643A JPH04243822A (en) | 1991-01-24 | 1991-01-24 | Calcium antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04243822A true JPH04243822A (en) | 1992-08-31 |
Family
ID=12088532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3022643A Pending JPH04243822A (en) | 1991-01-24 | 1991-01-24 | Calcium antagonist |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04243822A (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633022A2 (en) | 1993-07-09 | 1995-01-11 | Kureha Chemical Industry Co., Ltd. | Chondroprotective flavones |
EP0920870A1 (en) * | 1997-12-08 | 1999-06-09 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Flavanone-containing composition |
WO1999059606A1 (en) * | 1998-05-16 | 1999-11-25 | Mogam Biotechnology Research Institute | Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
WO2000015174A3 (en) * | 1998-09-15 | 2000-07-13 | Korea Inst Sci & Tech | Bioflavonoid as blood glucose level lowering agent |
JP2002080356A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
JP2002080355A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
JP2002080354A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Hypotensive agent composition |
JP2002145766A (en) * | 2000-11-08 | 2002-05-22 | Kao Corp | Prophylactic and therapeutic agent for hypotension |
JP2002154977A (en) * | 2000-09-05 | 2002-05-28 | Kao Corp | Composition for drinking and eating |
JP2002363075A (en) * | 2001-06-05 | 2002-12-18 | Kao Corp | Preventive and treating agent for hypertension |
EP1186297A3 (en) * | 2000-09-05 | 2003-12-17 | Kao Corporation | Agent for preventing, improving or treating hypertension |
WO2004041265A1 (en) * | 2002-11-06 | 2004-05-21 | Kao Corporation | Blood fluidity improving agent |
JP2005001998A (en) * | 2003-06-09 | 2005-01-06 | Api Co Ltd | Hypotensive agent, method for producing the same and propolis composition and food formulation |
WO2010049705A3 (en) * | 2008-10-31 | 2010-06-24 | Provexis Natural Products Limited | Therapeutic compositions comprising flavonoids |
US7750053B2 (en) | 2000-08-07 | 2010-07-06 | Kao Corporation | Compositions and methods for alleviating hypertension or preventing a rise in blood pressure |
CN104352864A (en) * | 2014-11-06 | 2015-02-18 | 北京京珠草本生物科技有限责任公司 | Traditional Chinese medicine composition for preventing and treating hypertension, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition |
CN107334813A (en) * | 2017-07-19 | 2017-11-10 | 力致(厦门)生物科技有限公司 | A kind of cubic parthenium extract and its preparation method and purposes |
-
1991
- 1991-01-24 JP JP3022643A patent/JPH04243822A/en active Pending
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633022A2 (en) | 1993-07-09 | 1995-01-11 | Kureha Chemical Industry Co., Ltd. | Chondroprotective flavones |
EP0920870A1 (en) * | 1997-12-08 | 1999-06-09 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Flavanone-containing composition |
WO1999059606A1 (en) * | 1998-05-16 | 1999-11-25 | Mogam Biotechnology Research Institute | Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
WO2000015174A3 (en) * | 1998-09-15 | 2000-07-13 | Korea Inst Sci & Tech | Bioflavonoid as blood glucose level lowering agent |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
US7750053B2 (en) | 2000-08-07 | 2010-07-06 | Kao Corporation | Compositions and methods for alleviating hypertension or preventing a rise in blood pressure |
EP1186297A3 (en) * | 2000-09-05 | 2003-12-17 | Kao Corporation | Agent for preventing, improving or treating hypertension |
JP2002080356A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
JP4641090B2 (en) * | 2000-09-05 | 2011-03-02 | 花王株式会社 | Antihypertensive agent |
JP2002154977A (en) * | 2000-09-05 | 2002-05-28 | Kao Corp | Composition for drinking and eating |
JP2002080354A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Hypotensive agent composition |
US7351436B2 (en) | 2000-09-05 | 2008-04-01 | Kao Corporation | Agent for preventing, improving or treating hypertension |
JP2002080355A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
US6991812B2 (en) * | 2000-09-05 | 2006-01-31 | Kao Corporation | Agent for preventing, improving or treating hypertension |
JP4520623B2 (en) * | 2000-11-08 | 2010-08-11 | 花王株式会社 | Antihypertensive agent |
JP2002145766A (en) * | 2000-11-08 | 2002-05-22 | Kao Corp | Prophylactic and therapeutic agent for hypotension |
EP1264596A3 (en) * | 2001-06-05 | 2003-01-08 | Kao Corporation | Use of a ferulic acid derivative as a preventive or remedy for hypertension |
US7534815B2 (en) * | 2001-06-05 | 2009-05-19 | Kao Corporation | Preventive or remedy for hypertension |
JP2002363075A (en) * | 2001-06-05 | 2002-12-18 | Kao Corp | Preventive and treating agent for hypertension |
WO2004041265A1 (en) * | 2002-11-06 | 2004-05-21 | Kao Corporation | Blood fluidity improving agent |
JP2005001998A (en) * | 2003-06-09 | 2005-01-06 | Api Co Ltd | Hypotensive agent, method for producing the same and propolis composition and food formulation |
WO2010049705A3 (en) * | 2008-10-31 | 2010-06-24 | Provexis Natural Products Limited | Therapeutic compositions comprising flavonoids |
CN104352864A (en) * | 2014-11-06 | 2015-02-18 | 北京京珠草本生物科技有限责任公司 | Traditional Chinese medicine composition for preventing and treating hypertension, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition |
CN107334813A (en) * | 2017-07-19 | 2017-11-10 | 力致(厦门)生物科技有限公司 | A kind of cubic parthenium extract and its preparation method and purposes |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04243822A (en) | Calcium antagonist | |
JPH0543469A (en) | Beta-glucuronidase inhibitor | |
JPH03271227A (en) | Therapeutic agent for treating diabetes mellitus | |
US4540709A (en) | Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran | |
JP2540871B2 (en) | Antihyperlipidemic agent | |
JP2687398B2 (en) | Aldose reductase inhibitor | |
JPH0383929A (en) | Blood sugar depressant | |
JPH0368516A (en) | Na+,k+-atpase inhibitor | |
JPH0368517A (en) | Aldose reductase inhibiting agent | |
JPH0952899A (en) | Leucotriene antagonist | |
JP2816664B2 (en) | Anti-dementia agent | |
JPH04208221A (en) | Lipoxygenase inhibitor | |
JPH03271226A (en) | Renal trouble remedying agent | |
JPH0717857A (en) | Circulatory disease therapeutic agent | |
JPH02243627A (en) | Remedy for angina pectoris | |
JPH0717859A (en) | Arachidonic acid dysbolism disease therapeutic agent | |
JP2541231B2 (en) | Novel compound and platelet aggregation inhibitor containing the compound as an active ingredient | |
JPH0285211A (en) | Novel phenetyl alcohol glycoside and immune inhibitor | |
JPH01224367A (en) | Polyacetylene compounds and 5-lipoxygenase inhibitor containing polyacetylene compounds as active component | |
JPH02264717A (en) | Inhibitor of blood platelet aggregation | |
JPH04187631A (en) | Agent for suppressing production of lipid peroxide | |
JPH02264718A (en) | Aldose reductase inhibitor | |
JPH07233060A (en) | Vasodilator | |
JPH0459788A (en) | New flavone-c-glycoside and aldose-reductase inhibitor containing the flavone-c-glycoside as active component | |
JPH0240394A (en) | 5-lipoxygenase inhibitor |